THANK YOU to Chris Gough for this excellent review of THE KISS ROOM!
Check it out:
I was scrolling through Facebook, looking for KISS related groups and pages. Why it took me until 2015 to do that, I have no idea. The first group to catch my attention was THE KISS ROOM. What's this? A KISS podcast? And as luck would have it, that day was KISS ROOM Friday. Being from Michigan, this was the perfect introductory episode for me. Matt interviewed coach Jim Neff of KISS Day in Cadillac fame. Live! On Montco Radio!
So there I am, sitting in my living room in Detroit, listening to this amazing KISS show that's broadcasting 30 minutes outside of Philadelphia, Pennsylvania. I'm also a huge fan of Stallone and Rocky, so this holds extra significance for me Matt Porter really is more than just the host. He becomes a friend. He works hard to keep the vibe positive, fun and inviting and that adds something personal to the experience. It's like a monthly family reunion. As they say... "it's a party".
THE KISS ROOM is everything you could hope for in a KISS radio show/podcast. Amazing guests, interviews, coverage of any and all current KISS happenings, music and THE KISS ROOM HOUSE BAND™. When I was a kid, just getting into KISS, I had MTV and Metal Edge magazine. And as cool as they were, neither of them could hold a candle to THE KISS ROOM. Anyone who is a fan of KISS should be listening to this show. For me, it's been almost 4 years now. And I still look forward to every episode as if it were my first.
KISS's original road manager, J.R. Smalling, has had a fund-raising campaign launched on his behalf. Smalling guided the fledgling KISS from 1974 through their breakthrough with ALIVE! and Destroyer, and is perhaps most remembered for being the man who literally invented perhaps the most famous concert introduction in rock: KISS's famous "You wanted the best..." intro. It is Smalling's voice, in fact, who begins the band's 1975 double-disc Alive!
Smalling was diagnosed with metastatic bone cancer in 2018. The outlook for that disease is dire with the average patient surviving anywhere from just six months to four years.
Fortunately, Smalling's oncologists have found an aggressive treatment plan that has halted the disease's progress in its tracks. The downside is that the medication and associated costs are crippling.